• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Radiopharmaceuticals - Global Strategic Business Report Product Image

Radiopharmaceuticals - Global Strategic Business Report

  • ID: 835008
  • June 2013
  • Region: Global
  • 279 Pages
  • Global Industry Analysts, Inc

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments:

- Diagnostic Radiopharmaceuticals
- Therapeutic Radiopharmaceuticals.

The report profiles 69 companies including many key and niche players such as:

- Actinium Pharmaceuticals Inc.
- Advanced Medical Isotope Corporation
- Alseres Pharmaceuticals Inc.
- Bayer HealthCare Pharmaceuticals
- Bracco Diagnostics Inc.
- Cardinal Health Inc.
- Covidien Plc
- Eli Lilly and Company
- Erigal Limited
- EUSA Pharma (Europe) Ltd.
- GE Healthcare
- IBA Group
- Immunomedics Inc.
- Jubilant Life Sciences Limited
- Lantheus Medical Imaging Inc.
- Medi-Radiopharma Ltd.
- Nordion Inc.
- Peregrine Pharmaceuticals Inc.
- PETNET Solutions Inc.
- Positron Corporation
- Singapore Radiopharmaceuticals Pte Ltd.
- Triad Isotopes Inc.

Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.

For information on site licence pricing please click on Enquire before buying.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
A. Diagnostic Radiopharmaceuticals
B. Therapeutic Radiopharmaceuticals

II. Executive Summary

1. INDUSTRY OVERVIEW
A Quick Primer
Market Scenario: Recession and the Road Ahead
Recession: A Period of Global Decline
The Road to Recovery
Outlook
Impact of Healthcare Budget Cuts in Developed Economies: A Review
Diagnostic Radiopharmaceuticals: The Dominant Segment
Promising Developments in Therapeutic Radiopharmaceuticals Underway

2. GROWTH DRIVERS & TRENDS
New Therapeutic Radiopharmaceuticals to Drive Global Market
Improvements in Imaging Technology
Rise in International Investments for Radiopharmaceuticals
Bayer Algeta Partnership for Alpharadin
Lutathera
AREVA Med
AtlabPharma and Cornell Well Medical Center
Zevalin's Landmark FDA Approval Offers New Opportunities
Improved Reimbursement for Therapeutic Radiopharmaceuticals
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth
World Cancer Statistics - Incidence and Mortality Data
Table 1: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
Table 2: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer- Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
Table 3: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart)
Table 4: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)
Table 5: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)
Table 6: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)
Table 7: World Breast Cancer Statistics: Top 20 Countries with Highest Breast Cancer Rates (includes corresponding Graph/Chart)
Cancer Prone Sites based on Age
Targeted Radionuclide Therapy: Gaining Ground in Cancer Treatment
Intra-operative Lymphatic Mapping (ILM): Creating New Opportunities for Radiopharmaceuticals in Cancer Detection
Emergence of Radioisotope Based Personalized Therapy Bodes Well for the Market
Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
Widespread Awareness among Practitioners & Patients: The Need of the Hour
Cardiology: An Important Sector for Radiopharmaceuticals
Expansion of Molecular Imaging Platform is Key to Future Growth
Battling Alzheimer's Disease - A Powerful Market Force
Table 8: Elderly Population (65+ Years) as a Percentage of the Total Population: 2000 & 2025 (includes corresponding Graph/Chart)
Growing Demand for PET to Drive up Demand
Opportunities Increasing for Fluorine-Based Myocardial Perfusion Agents
Innovative PET Biomarkers in the Offing for Oncology
Hypoxia Imaging Presents Opportunities for PET
Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth
Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic Radiopharmaceuticals
International Collaborations Give a Thumbs Up to Drug Development
Key Statistical Data
Table 9: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Weekly Demand by Region (includes corresponding Graph/Chart)
Table 10: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Production by Reactor (includes corresponding Graph/Chart)
Reactors Producing Cobalt 60 & Molybdenum 99
Table 11: Global Projected Demand for Mo-99 in Emerging and Mature Markets for the Years 2020 and 2030 (includes corresponding Graph/Chart)

3. MARKET CHALLENGES
High Costs of Drug Development Piques Manufacturers
Supply Shortages: A Niggling Cause of Concern
Canadian Scientists Discover Means to Address Supply Shortages
Price Sensitivity & Competition from Alternatives Limit Market Potential
Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
Unfounded Fears of Radiation Exposure Hinder Growth
Bottlenecks in Developing Markets

4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT
Primer
Lutathera for Neuroendocrine Cancer
Alpharadin for Bone Cancer Treatment
Actimab for Leukemia and Blood Borne Cancers
Lead-212 Alpha Therapy for Metastasized Abdominal Cancers
Lu-177-J591 PSMA Antibody for Prostate Cancer
Indium-111-Pentetreotide for Neuroendocrine Tumors
Yttrium-90 Clivatuzumab for Pancreatic Cancer
CycloSam for Bone Cancer
Phospholid Ether Tumor Targeting

5. IMAGING AGENTS - AN OVERVIEW
A Quick Primer
Growth Drivers
Market Restraints
Significance of Technological Advancements
X-Ray Contrast Media: Giving Way to Emerging Modalities
Medical Reimbursement: A Critical Factor
Market Structure
Select Players by Segment

6. NUCLEAR MEDICINE - AN OVERVIEW
Nuclear Medicine - An Introduction
Growth Drivers in a Nutshell
Market Shifts to Hybrid Imaging

7. PRODUCT OVERVIEW
Radiopharmaceuticals: A Definition
Mechanism of Action
Application of Radiopharmaceuticals
Radioactive Tracers for Diagnostic Imaging
Therapeutics
Research
Sterilization
Classification of Radiopharmaceuticals
Diagnostic Radiopharmaceuticals
Commonly Used Diagnostic Radiopharmaceutical Agents
Major Isotopes and their Diagnostic Applications
Advantages
Classification
Cardiology Diagnostics
Non-cardiology Diagnostics
Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
Planar Imaging
Positron Emission Tomography (PET)
Advantages
Applications of PET
Commonly used Radioisotopes in PET Scans
Major PET Isotopes and their Applications
Single Photon Emission Computed Tomography (SPECT)
Applications of SPECT
Commonly used Radioisotopes in SPECT Scans
Therapeutic Radiopharmaceuticals
Characteristics of Therapeutic Radiopharmaceuticals
Commonly used Therapeutic Agents
Major Isotopes and their Therapeutic Applications
Radiopharmaceuticals for Thyroid Therapy
Radiopharmaceuticals for Cancer Therapy
Radiopharmaceuticals for Neuroendocrine Tumors
Radiopharmaceuticals for Radiosynoviorthesis Therapy
Radiopharmaceuticals for Bone Pain Palliation Therapy
Radiopharmacy: A Key Link in the Distribution Chain
Table 12: US Radiopharmacies Market (2010): Percentage Share Breakdown of SPECT Doses Sold by Company (includes corresponding Graph/Chart)

8. PRODUCT INNOVATIONS/INTRODUCTIONS
Positron Launches Advanced PosiRx Pharmacy Automation Systems
BARC Launches Indigenous Radiopharmaceuticals- Powered Scans
Rapidscan Pharma Solutions EU and GE Healthcare Unveil Rapiscan®
Positron Launches PosiRx

9. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST- A PERSPECTIVE BUILDER
GE Healthcare Enhances Radiopharmaceuticals Product Portfolio
IBA Molecular Obtains Positive Opinion to Market Dopacis in Europe
BARC Develops Radiopharmaceuticals for Cancer Treatment
Medrad Mounts Intego™ PET Infusion System at UPMC
IBA Molecular Announces the Launch of Cyclone ® 18 Twin
Molecular Insight Develops New Radio-iodinated Molecules
Immunomedics Develops New Antibody for Radio-immunotherapy

10. RECENT INDUSTRY ACTIVITY
Advanced Accelerator Applications Expands Radiopharmaceutical Manufacturing Network
Advanced Accelerator Applications Inks Partnership Agreement with Uwrc Spoka Z Ograniczon Odpowiedzialno Ci
Eli Lilly to Purchase Two Radiopharmaceutical Imaging Agents from Siemens
UPPI Inks Contract with Novation
Dalton Inks Manufacturing Partnership with Clarity Pharmaceuticals
Lantheus Medical Imaging Extends Agreement with Nordion
Lantheus Medical Imaging and Jubilant HollisterStier Enter into Agreement
NCM Reveals New Advanced PET Radiopharmaceutical Manufacturing Center
Turkey Inaugurates First Particle Accelerator
SK Capital and IBA Sign Agreement to Setup IBA Molecular Imaging
Novelos Therapeutics Pockets Cellectar Inc
Southern Research Institute Inks Agreement with Biomedical Research Foundation
IBA Acquires Minority Stake in PET Net Solutions
Amerinet Inks Group Purchasing Agreement with Positron
Premier Purchasing Partners Awards Supplier Contract to Lantheus Medical Imaging
MDS Nordion Inks Collaborative Agreement with Avid Radiopharmaceuticals
Devicor™ Medical Products Acquires Neoprobe®
UHN and CPDC Form Joint Venture
AstraZeneca Inks Licensing Agreement with Neoprobe
Cardinal Health Unveils Molecular Imaging Collaboration Center in Phoenix Region

11. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER
Covidien Enters into Agreement with IAE POLATOM
Dalat Nuclear Research Institute Inks Agreement with Probactive Biotech
Principio Wins Licensing Agreement from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Covidien Inks Definitive Agreement with Triad Isotopes
Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals
Lumiphore Inks Agreement with Algeta
IBA Renews Contract with Servicio Andaluz de Salud
Lumiphore and Algeta Ink Partnership Agreement
Positron and Covidien Ink Agreement
PETNET Solutions Expands PET Radiopharmaceutical Network
Triad Isotopes Acquires Radiopharmacy Network of Covidien
Principio Receives Exclusive Technological Development License from Hopkins Sidney Kimmel Comprehensive Cancer Center
PETNET Solutions Renews Supply Agreement with Paul Strickland Scanner Centre
IBA Molecular Obtains Marketing Approval for Filtracis Radiopharmaceutical Kit
DHA Inks MoU with DCD
Algeta Signs Agreement with Bayer
Antisoma Collaborates with Bryan Oncor
Karpov Institute Enters into Collaboration with MDS Nordion
MDS Nordion Establishes Glucotrace Facility
Draximage Inks Agreement with Guerbet
Eczacybathorny-Monrol Collaborates with IBA
Siemens Healthcare Signs Agreement with Calypso Medical
Molecular Insight Signs Agreement with BioMedica Life Sciences
Bayer Schering Signs Agreement with Algeta
IBA Inks Agreement with Aposense
Draxis Receives Approval from Health Canada for Generic Sestamibi
Cyclopharm and Alfred Health Solutions Form Joint Venture
Guerbet Inks Distribution Agreement with Draximage
Ion Beam Applications Collaborates with Eczacibasi-Monrol Nuclear Products

12. FOCUS ON SELECT PLAYERS
Actinium Pharmaceuticals Inc (US)
Advanced Medical Isotope Corporation (US)
Alseres Pharmaceuticals, Inc (US)
Bayer HealthCare Pharmaceuticals Inc (US)
Bracco Diagnostics, Inc. (US)
Cardinal Health, Inc (US)
Covidien Plc (Ireland)
Eli Lilly and Company (US)
Erigal Limited (UK)
EUSA Pharma (Europe) Ltd. (UK)
GE Healthcare (UK)
IBA Group (Belgium)
Immunomedics, Inc. (US)
Jubilant Life Sciences Limited (India)
Lantheus Medical Imaging Inc (US)
Medi-Radiopharma Ltd (Hungary)
Nordion Inc (Canada)
Peregrine Pharmaceuticals, Inc. (US)
PETNET Solutions Inc (US)
Positron Corporation (US)
Singapore Radiopharmaceuticals Pte Ltd (Singapore)
Triad Isotopes, Inc. (US)

13. GLOBAL MARKET PERSPECTIVE
Table 13: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 14: World Historic Review for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 15: World 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American for 2005, 2013 & 2018 (includes corresponding Graph/Chart)
Table 16: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 17: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 18: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart)
Table 19: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 20: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 21: World 15-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
Outlook
Industry Structure
Production Scenario
Dependence on Imports
DOE's Flawed Isotope Program Causes Shortage Fears in the US
Regulatory Scenario
Thorny Regulations Dampen New Product Development
FDA's Antidote
Overview of Medicare Reimbursements
Medicare Payment Settings for Contrast Agents and Radiopharmaceuticals
Payments for Radiology Services
Medicare Coverage
Billing and Payment on Medicare Professional Claims
Payment Conditions for Radiology Services
Services Furnished in Hospitals to Inpatients
Services Furnished in Hospitals to Outpatients
Services Furnished in Skilled Nursing Facilities (SNF)
Services Furnished by Rural Health Clinics (RHC) and Federally Qualified Health Centers (FQHC)
Implications of Reimbursement Changes on Radiology
Radiopharmaceutical Reimbursement in the US: Who's Under the Umbrella
Diagnostic Radiopharmaceuticals Bundled As Supplies under Medicare Reimbursements
Concerns over Bundling of Zevalin into Diagnostic Radiopharmaceuticals Allayed
Improved Reimbursement for Therapeutic Radiopharmaceuticals
Market Overview
Sanguine Growth On Cards
Expanding Diagnostic Applications Will Stimulate Future Growth
Nuclear Cardiology Products Drive Up Diagnostic Radiopharmaceuticals Market
Cardiovascular Imaging To Lead Volume Growth
Cardiolite Loses Market Share to Generics
Table 22: The US Diagnostic Radiopharmaceutical Agents Market (2012): Percentage Share Breakdown of Procedure Volume by Imaging Procedure - SPECT and PET (includes corresponding Graph/Chart)
Table 23: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)
Table 24: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart)
New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals Market
Table 25: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications (includes corresponding Graph/Chart)
Installed Base of SPECT Scanners
Table 26: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes corresponding Graph/Chart)
Installed Pet Scanners in US
US FDG Market
Table 27: US FDG Market (2012): Percentage Share Breakdown of Procedure Volume by Procedure Type - Oncology, Neurology and Cardiology (includes corresponding Graph/Chart)
Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market
Market Share Statistics
Table 28: US Market for Diagnostic Radiopharmaceuticals Agents (2011): Percentage Market Share Breakdown for Leading Players (includes corresponding Graph/Chart)
Table 29: US Market for Therapeutic Radiopharmaceuticals (2012): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics - Bone Palliation, Non-Hodgkins Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart)
Table 30: US Market for Therapeutic Radiopharmaceutical Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart)
Table 31: US Market for Radiopharmaceutical Bone Palliation Procedures (2012): Percentage Share Breakdown by Key Radiotherapeutics - Metastron, Quadramet and Sr
(includes corresponding Graph/Chart)
Table 32: Radiopharmacy Market in the US (2012): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart)
Product Launches
Strategic Corporate Developments
Select Players
B.Market Analytics
Table 33: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 34: US Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 35: US 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
Outlook
Canadian Scientists Lead the Discovery of Remedy for Supply Shortages
An Overview of Medical Imaging Market
Regulatory and Legal Restrictions
Strategic Corporate Developments
Select Players
B.Market Analytics
Table 36: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 37: Canadian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 38: Canadian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

3. JAPAN
A.Market Analysis
Outlook
Reimbursement Issues
Japanese Healthcare System: An Overview
Fast Facts
Government Initiatives
B.Market Analytics
Table 39: Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 40: Japanese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 41: Japanese 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4. EUROPE
A.Market Analysis
Outlook
Competitive Scenario
Key Statistics
Table 42: European Radiopharmaceuticals Market (2010): Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart)
Table 43: European Diagnostic Radiopharmaceuticals Market (2012): Percentage Share Breakdown of Value Sales by Imaging Modalities - SPECT and PET (includes corresponding Graph/Chart)
Market Trends
New Applications and Products Augur Good Market Prospects
Increasing PET and PET/CT Applications Will Kindle Growth
B.Market Analytics
Table 44: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 45: European Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 46: European 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
Table 47: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 48: European Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 49: European 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4a. FRANCE
A.Market Analysis
Outlook
Growth Stimulants
B.Market Analytics
Table 50: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 51: French Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 52: French 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4b. GERMANY
A.Market Analysis
Outlook
B.Market Analytics
Table 53: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 54: German Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 55: German 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4c. ITALY
A.Market Analysis
Outlook
B.Market Analytics
Table 56: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 57: Italian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 58: Italian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4d. THE UNITED KINGDOM
A.Market Analysis
Outlook
Strategic Corporate Development
Select Players
B.Market Analytics
Table 59: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 60: UK Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 61: UK 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4e. SPAIN
A.Market Analysis
Outlook
Recent Industry Activity
B.Market Analytics
Table 62: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 63: Spanish Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 64: Spanish 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4f. RUSSIA
A.Market Analysis
Outlook
B.Market Analytics
Table 65: Russian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 66: Russian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 67: Russian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
4g. REST OF EUROPE
A.Market Analysis
Outlook
Market Overview
Strategic Corporate Developments
Select players
B.Market Analytics
Table 68: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 69: Rest of Europe Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 70: Rest of Europe 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A.Market Analysis
Outlook
ANSTO: Leading the Radiopharmaceuticals Market
B.Market Analytics
Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region
China, India and Rest of Asia-Pacific Markets Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 72: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 73: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for India, China and Rest of Asia-Pacific Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
Table 74: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 75: Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 76: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
5a. CHINA
A.Market Analysis
Outlook
Medical Imaging Device Market - An Overview
Increasing Expenditure on Healthcare Sector
B.Market Analytics
Table 77: Chinese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 78: Chinese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 79: Chinese 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
5b. INDIA
A.Market Analysis
Outlook
Department of Atomic Energy Controls the Supply
Product Launch
Jubilant Life Sciences Limited - A Key Player
B.Market Analytics
Table 80: Indian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 81: Indian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 82: Indian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
5c. REST OF ASIA-PACIFIC
A.Market Analysis
Outlook
Singapore Radiopharmaceuticals Pte Ltd - A Key Player
B.Market Analytics
Table 83: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 84: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 85: Rest of Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

6. MIDDLE EAST
A.Market Analysis
Outlook
B.Market Analytics
Table 86: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 87: Middle East Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 88: Middle-East 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

7. LATIN AMERICA
A.Market Analysis
Outlook
B.Market Analytics
Table 89: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 90: Latin American Historic Review for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 91: Latin American 15-Year Perspective for Radiopharmaceuticals by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
Table 92: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 93: Latin American Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 94: Latin American 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
7a. BRAZIL
A.Market Analysis
Outlook
B.Market Analytics
Table 95: Brazilian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 96: Brazilian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 97: Brazilian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
7b. REST OF LATIN AMERICA
A.Market Analysis
Outlook
B.Market Analytics
Table 98: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment
Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
Table 99: Rest of Latin America Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
Table 100: Rest of Latin America 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 69 (including Divisions/Subsidiaries - 79)
The United States (36)
Canada (2)
Japan (1)
Europe (28)
- France (2)
- Germany (2)
- The United Kingdom (4)
- Italy (2)
- Spain (1)
- Rest of Europe (17)
Asia-Pacific (Excluding Japan) (9)
Latin America (1)
Africa (1)
Middle East (1)

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos